ArticleClinical and vaccine immunology : CVI2011
Plasma antibody profiles as diagnostic biomarkers for tuberculosis.
Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses.PloS one · 2021Trial
- Blinded trial of multiplex serodiagnostic test in India for diverse forms of active tuberculosis.Microbiology spectrum · 2026Article
- A proteome-wide atlas of humoral immunity toFrontiers in immunology · 2026Article
- Antibodies as key mediators of protection againstFrontiers in immunology · 2024Review
- Lipid Mediators and Cytokines/Chemokines Display Differential Profiles in Severe versus Mild/Moderate COVID-19 Patients.International journal of molecular sciences · 2023Article
- Numerical Assessment of a Metal-Insulator-Metal Waveguide-Based Plasmonic Sensor System for the Recognition of Tuberculosis in Blood Plasma.Micromachines · 2023Article
- Article
- Differential levels of anti-Frontiers in medicine · 2023Article
- Serological analysis reveals differential antibody responses between TB patients and latently infected individuals from the TB endemic country of Mozambique.Frontiers in medicine · 2023Article
- Antibodies as clinical tools for tuberculosis.Frontiers in immunology · 2023Review
- Automated machine learning for endemic active tuberculosis prediction from multiplex serological data.Scientific reports · 2021Article
- Aptamer-Based Diagnostic Systems for the Rapid Screening of TB at the Point-of-Care.Diagnostics (Basel, Switzerland) · 2021Review
- Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting.PloS one · 2021Article
- Evaluation of multi-antigen serological screening for active tuberculosis among people living with HIV.PloS one · 2020Article
- Diagnostic performance and problem analysis of commercial tuberculosis antibody detection kits in China.Military Medical Research · 2018Article
- Article
- Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Identification of Antibody Targets for Tuberculosis Serology using High-Density Nucleic Acid Programmable Protein Arrays.Molecular & cellular proteomics : MCP · 2017Article
- Evaluation of antibody responses to panels of M. tuberculosis antigens as a screening tool for active tuberculosis in Uganda.PloS one · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
Two billion people are infected with Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), worldwide. Ten million to 20 million of the infected individuals develop disease per year. TB is a treatable disease, provided that it is diagnosed in a timely manner. The current TB diagnostic methods are subjective, inefficient, or not cost-effective. Antibody-based blood tests can be used efficiently and cost-effectively for TB diagnosis. A major challenge is that different TB patients generate antibodies against different antigens. Therefore, a multiplex immunoassay approach is needed. We have developed a multiplex panel of 28 M. tuberculosis antigen-coated microbeads. Plasma samples were obtained from over 300 pulmonary TB patients and healthy controls in a country where TB is endemic, Pakistan. Multiplex data were analyzed using computational tools by multivariate statistics, classification algorithms, and cluster analysis. The results of antibody profile-based detection, using 16 selected antigens, closely correlated with those of the sputum-based diagnostic methods (smear microscopy and culture) practiced in countries where TB is endemic. Multiplex microbead immunoassay had a sensitivity and specificity of approximately 90% and 80%, respectively. These antibody profiles could potentially be useful for the diagnosis of nonpulmonary TB, which accounts for approximately 20% of cases of disease. Since an automated, high-throughput version of this multiplex microbead immunoassay could analyze thousands of samples per day, it may be useful for the diagnosis of TB in millions of patients worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.